Search

HLA-A*26:247 differs from HLA-A*26:01:01:01 by one nucleotide substitution in codon 245 in exon 4., (© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)

HLA-A*24:587 differs from HLA-A*24:02:01:01 by one nucleotide substitution in codon 220 in exon 4., (© 2023 The Authors. HLA: Immune Response Genetics published by John Wiley & Sons Ltd.)

HLA-A*24:585 differs from HLA-A*24:02:01:01 by one nucleotide substitution in codon -15 in exon 1., (© 2023 The Authors. HLA: Immune Response Genetics published by John Wiley & Sons Ltd.)

HLA-A*01:419 differs from HLA-A*01:01:01:03 by one nucleotide substitution in codon 200 in exon 4., (© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)

HLA-A*11:422 differs from HLA-A*11:01:01:01 by one nucleotide substitution in codon 285 in exon 5., (© 2022 The Authors. HLA: Immune Response Genetics published by John Wiley & Sons Ltd.)

HLA-A*03:436 differs from HLA-A*03:01:01:05 by one nucleotide substitution in codon 26 in exon 2., (© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)

HLA-A*24:564 differs from HLA-A*24:02:01:01 by one nucleotide substitution in codon 240 in exon 4., (© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)

HLA-A*30:02:28 differs from HLA-A*30:02:01:01 by one nucleotide substitution in codon 47 in exon 2., (© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)

HLA-A*24:538 differs from HLA-A*24:02:01:01 by one nucleotide substitution in codon -21 in exon 1., (© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)

HLA-A*36:12 differs from HLA-A*36:01:01:01 by one nucleotide substitution in codon 211 in exon 4., (© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)

HLA-A*01:367 differs from HLA-A*01:01:01:01 by one nucleotide substitution in codon 271 in exon 4., (© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)

HLA-A*26:01:66 differs from HLA-A*26:01:01:01 by a single nucleotide change in codon 41 in exon 2., (© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)

HLA-A*11:376 differs from HLA-A*11:01:01:01 by one nucleotide substitution in codon 168 in exon 3., (© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)

HLA-A*02:939 differs from HLA-A*02:01:01:01 by one nucleotide substitution in codon 222 in exon 4., (© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)

HLA-A*02:944 differs from HLA-A*02:01:01:01 by one nucleotide substitution in Codon 114 in Exon 3., (© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)

HLA-A*11:361 differs from HLA-A*11:01:01:01 by one nucleotide substitution in codon 138 in exon 3., (© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)

HLA-A*26:199 differs from HLA-A*26:01:01:01 by one nucleotide substitution in codon 261 in exon 4., (© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)

HLA-A*11:324 differs from HLA-A*11:01:01:01 by one nucleotide substitution in codon 317 in exon 6., (© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)

HLA-A*03:350 differs from HLA-A*03:01:01:01 by one nucleotide substitution in codon 1 in exon 1., (© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)

HLA-A*33:170 differs from HLA-A*33:01:01:01 by one nucleotide substitution at codon 222 in exon 4., (© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)

HLA-A*30:135 differs from HLA-A*30:01:01 by one nucleotide substitution at codon 304 in exon 5., (© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)

Polymerase chain reaction sequence-specific oligonucleotide is commonly used for HLA-typing. We replaced our LabType SSO HD (HD) kits with LabType SSO XR (XR) kits (One Lambda, Inc., Canoga Park, California) for HLA-A, -B, and -DRB1 following acquisition of a LABScan3D analyzer. The XR kits have more bead regions than the HD kits, allowing for an extended number of probes and exon coverage. They are claimed to improve typing resolution and to diminish the number of allele ambiguities, including common and well-documented (CWD) and null alleles to be resolved. We retrospectively selected patients who had their first HLA-typing performed with the HD kits and their second determination with the XR kits between 2015 and 2016. Forty-two patients were selected for HLA-A typing comparison, and 48 for HLA-B and 41 for HLA-DRB1. XR kits significantly decreased the number of allele ambiguities for HLA-A and -B. On the other hand, the improvement was limited for the HLA-DRB1 locus. The XR kits did not resolve all the CWD HLA allele ambiguities, which may be important for organ and/or hematopoietic stem cell transplantations. The XR kits eliminated 88%, 62%, and 27% of null allele ambiguities for HLA-A, -B, and -DRB1 loci, respectively. In conclusion, the XR kits allow for a significant improvement of HLA-typing resolution for HLA-A and -B loci in comparison with HD kits. In contrast, the number of oligonucleotides in the XR HLA-DRB1 kit should be extended to include exon 3 at the very least. It could also be interesting to include oligonucleotides allowing HLA-DRB3, 4, and 5 typing., (© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)

HLA-A*24:391 differs from HLA-A*24:02:01:01 by one nucleotide substitution at position 33., (© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)